Related Experiment Video
Updated: Jul 29, 2025
Author Spotlight: Exploring the Antibacterial Effects of Zinc Oxide Nanoparticles in Overcoming Antibiotic Resistance
Published on: September 27, 2024
Fighting Methicillin-Resistant Staphylococcus aureus with Targeted Nanoparticles
Stéphanie Andrade1,2, Maria J Ramalho1,2, Sílvio B Santos3
1LEPABE-Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.
Abstract:
Antimicrobial resistance (AMR) is considered one of the greatest threats to global health. Methicillin-resistant Staphylococcus aureus (MRSA) remains at the core of this threat, accounting for about 90% of S. aureus infections widespread in the community and hospital settings. In recent years, the use of nanoparticles (NPs) has emerged as a promising strategy to treat MRSA infections. NPs can act directly as antibacterial agents via antibiotic-independent activity and/or serve as drug delivery systems (DDSs), releasing loaded antibiotics. Nonetheless, directing NPs to the infection site is fundamental for effective MRSA treatment so that highly concentrated therapeutic agents are delivered to the infection site while directly reducing the toxicity to healthy human cells. This leads to decreased AMR emergence and less disturbance of the individual's healthy microbiota. Hence, this review compiles and discusses the scientific evidence related to targeted NPs developed for MRSA treatment.
Insights
Targeted nanoparticles offer a promising strategy against Methicillin-resistant Staphylococcus aureus (MRSA) infections. This approach enhances drug delivery to infection sites, reducing toxicity and combating antimicrobial resistance (AMR).
Area of Science:
- Nanotechnology and Materials Science
- Infectious Diseases and Microbiology
- Pharmacology and Drug Delivery
Background:
- Antimicrobial resistance (AMR) is a critical global health challenge, with Methicillin-resistant Staphylococcus aureus (MRSA) infections posing a significant threat in both community and hospital settings.
- MRSA accounts for a substantial proportion of Staphylococcus aureus infections, highlighting the urgent need for novel therapeutic strategies.
- Nanoparticles (NPs) are emerging as a key area of research for combating MRSA due to their potential as direct antibacterial agents and as drug delivery systems (DDSs).
Purpose of the Study:
- To review and discuss the scientific evidence concerning targeted nanoparticles developed for the treatment of MRSA infections.
- To highlight the advantages of directing NPs to infection sites for enhanced therapeutic efficacy and reduced host toxicity.
- To explore how targeted NP delivery can mitigate the emergence of AMR and preserve healthy microbiota.
Main Methods:
- Comprehensive literature review of studies focusing on targeted nanoparticles for MRSA treatment.
- Analysis of NP mechanisms of action, including direct antibacterial activity and antibiotic delivery.
- Evaluation of evidence for targeted NP delivery systems in preclinical and clinical settings.
Main Results:
- Targeted NPs demonstrate potential for direct antibacterial activity against MRSA, independent of traditional antibiotics.
- NPs can be engineered as DDSs to deliver antibiotics specifically to infection sites, increasing local drug concentration.
- Targeted delivery of NPs reduces systemic toxicity to healthy human cells and minimizes disruption of the host's microbiota.
Conclusions:
- Targeted nanoparticles represent a promising therapeutic strategy for combating MRSA infections.
- This approach offers a dual benefit of direct antimicrobial action and enhanced antibiotic delivery, while minimizing side effects.
- Further research into targeted NPs is crucial for developing effective treatments against AMR and improving patient outcomes.
